MRD in CLL: some answers, many questions

In this issue of Blood, Wang et al compare the minimal residual disease (MRD) rate and outcome of patients with CLL treated with continuous ibrutinib plus 6 cycles of rituximab (IR) with that of those treated with FCR (fludarabine, cyclophosphamide and rituximab).(1) This study provides comparative data on the use of MRD in the management of CLL and emphasizes several pressing issues.

Automated summary

This study compares the MRD rates and outcomes of CLL patients treated with different regimens, providing valuable insights into the management of CLL.